长效注射抗精神病药与常规治疗对早期精神分裂症首次住院时间的影响:一项随机临床试验
PRELAPSE试验为集群随机设计,在美国19个州39家精神卫生中心纳入489例病程少于5年、年龄18-35岁的早期精神分裂症患者,比较鼓励使用长效阿立哌唑单水合物(AOM)与常规治疗对首次精神科住院时间的影响。结果显示AOM组首次住院风险显著低于常规治疗组(HR 0.56,95%CI 0.34-0.92;
要点
- 早期精神分裂症患者中,鼓励使用长效阿立哌唑可显著延迟首次住院时间。
- 预防1例额外住院需治疗7例患者。
核心结论
- 对于早期精神分裂症患者,使用长效注射抗精神病药可显著延迟首次住院时间,具有重要的个人和经济意义。
- 临床医生应更广泛地考虑对早期病程患者使用长效注射抗精神病药。
研究设计与样本
- 研究在美国19个州39家精神卫生中心开展,19家诊所随机分配至鼓励使用长效阿立哌唑单水合物(AOM)组,20家分配至常规治疗(临床医生选择,CC)组。
- 纳入标准为结构化临床访谈确认的精神分裂症诊断、终身抗精神病药使用少于5年、年龄18至35岁。
- AOM站点识别576例潜在合格参与者,234例(40.6%)入组;CC站点识别685例,255例(37.2%)入组;共489例参与者,其中男性368例(75.3%),平均年龄25.2岁(SD 4.2),225例(46.0%)终身抗精神病药使用不超过1年。
主要发现
- AOM组首次住院前平均生存时间为613.7天(95%CI 582.3-645.1天),CC组为530.6天(95%CI 497.3-563.9天)。
- AOM组生存概率为0.73(95%CI 0.65-0.83),CC组为0.58(95%CI 0.50-0.67)。
- 预防1例额外住院需治疗7例患者(AOM相比CC)。
关键数值与推荐
- 主要结局为首次精神科住院时间,基于每2个月参与者访谈、每4个月服务使用资源表及其他来源(如健康记录)判定。
- 潜在事件由对治疗分组设盲的独立委员会裁定。
- CC站点治疗无限制(包括使用长效注射抗精神病药);AOM站点除阿立哌唑单水合物须在美国食品药品监督管理局批准指南内处方外无其他限制。
临床怎么用
- 临床医生应更广泛地考虑对早期精神分裂症患者使用长效注射抗精神病药以延迟住院。
- 鼓励使用长效阿立哌唑单水合物的策略可降低早期精神分裂症患者的首次住院风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Long-acting injectable antipsychotics (LAIs) can potentially reduce hospitalization risk by enhancing medication adherence but are rarely considered for early-phase schizophrenia treatment. OBJECTIVE: To determine whether encouraging use of a LAI compared with usual care delays the time to first hospitalization with patients with early-phase illness. DESIGN, SETTING, AND PARTICIPANTS: The Prevention of Relapse in Schizophrenia (PRELAPSE) trial was cluster randomized with a follow-up duration of 2 years. The study began in December 2014, was completed in March 2019, and was conducted in 39 mental health centers in 19 US states. Site randomization assigned 19 clinics to encourage treatment with long-acting aripiprazole monohydrate (aripiprazole once monthly [AOM] condition) and 20 to provide treatment as usual (clinician's choice [CC] condition). Participant eligibility criteria included (1) schizophrenia diagnosis confirmed by a structured clinical interview, (2) fewer than 5 years of lifetime antipsychotic use, and (3) age 18 to 35 years. The AOM sites identified 576 potentially eligible participants, of whom 234 (40.6%) enrolled; CC sites identified 685 potentially eligible participants, of whom 255 (37.2%) enrolled. INTERVENTIONS: There were no restrictions on treatment at CC sites (including using LAIs) or at AOM sites with the exception that aripiprazole monohydrate had to be prescribed within US Food and Drug Administration-approved guidelines. MAIN OUTCOMES AND MEASURES: The primary outcome was time to first psychiatric hospitalization based on participant interviews every 2 months, the service use resource form administered every 4 months, and other sources (eg, health records) as available. Potential events were adjudicated by an independent committee masked to treatment assignment. RESULTS: The 489 participants (368 men [75.3%]) had a mean (SD) age of 25.2 (4.2) years and 225 (46.0%) had 1 year or less lifetime antipsychotic use. Fifty-two AOM (22%) and 91 CC participants (36%) had at least 1 hospitalization. The mean survival time until first hospitalization was 613.7 days (95% CI, 582.3-645.1 days) for AOM participants and 530.6 days (95% CI, 497.3-563.9 days) for CC participants. For time to first hospitalization, the hazard ratio was 0.56 (95% CI, 0.34- 0.92; P = .02), favoring AOM. Survival probabilities were 0.73 (95% CI, 0.65-0.83) for AOM participants and 0.58 (95% CI, 0.50-0.67) for CC participants. The number needed to treat to prevent 1 additional hospitalization was 7 participants treated with AOM compared with CC. CONCLUSIONS AND RELEVANCE: Long-acting injectable antipsychotic use by patients with early-phase schizophrenia can significantly delay time to hospitalization, a personally and economically important outcome. Clinicians should more broadly consider LAI treatment for patients with early-phase illness. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02360319.
引用
- Kane JM, Schooler NR, Marcy P, et al. Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial. JAMA Psychiatry. 2020. PMID: 32667636. doi:10.1001/jamapsychiatry.2020.2076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。